October 25, 2018 | Chip Kahn
Category: Financing, Medicare, Pharmaceuticals
We agree with the President that it is time to reduce the drug tab for Americans, and actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.
It is important that the plan aim at protecting patients and does not impede the freedom of physicians to prescribe the precise drug therapies their patients need.
- Public Charge Rule Could Have Chilling Effect on Access to Care
- REPORT: A Medicare Public Option Puts Majority of Rural Hospitals at Risk
- In the News – FAH’s Study on Modernizing the HCAHPS Patient Experience Survey
- Joint Statement from National Hospitals Associations on Proposed CY 2020 OPPS Rule